PUBLISHER: The Business Research Company | PRODUCT CODE: 1945472
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945472
A left ventricular assist device (LVAD) serves as a mechanical pump implanted in heart failure patients, assisting the heart's lower left chamber (left ventricle) in pumping blood to the aorta and throughout the body.
The primary types of left ventricular assist devices include transcutaneous left ventricular assist devices and implantable left ventricular assist devices. A transcutaneous left ventricular assist device is characterized by having both an external power supply and an internal pump located inside the body. Tubes connect the pump to the heart through small openings in the abdomen. This type of LVAD is often employed for short-term support during or following surgery. Left ventricular assist devices can have either pulsatile or non-pulsatile flows, and they are used in various therapeutic approaches such as bridge-to-recovery (BTR) therapy, bridge-to-transplant (BTT) therapy, destination therapy, and bridge-to-candidacy (BTC) therapy. Cardiology centers and hospitals typically utilize these devices for patient care.
Tariffs are impacting the left ventricular assist devices market by increasing costs of imported precision components, biocompatible materials, electronic controllers, and manufacturing equipment used in implantable and transcutaneous LVAD systems. Hospitals and cardiac centers in North America and Europe are most affected due to reliance on specialized imported components, while Asia-Pacific faces higher production costs for export-oriented device manufacturing. These tariffs are increasing device pricing and procurement complexity for healthcare providers. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic medical device production capabilities.
The left ventricular assist devices market research report is one of a series of new reports from The Business Research Company that provides left ventricular assist devices market statistics, including left ventricular assist devices industry global market size, regional shares, competitors with a left ventricular assist devices market share, detailed left ventricular assist devices market segments, market trends and opportunities, and any further data you may need to thrive in the left ventricular assist devices industry. This left ventricular assist devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The left ventricular assist devices market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.9 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of advanced heart failure, limited availability of donor hearts, expansion of specialized cardiac care centers, improvements in surgical implantation techniques, rising clinical acceptance of mechanical circulatory support.
The left ventricular assist devices market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing aging population with cardiac conditions, rising demand for long-term heart failure management solutions, advancements in biocompatible materials, growing integration of remote monitoring technologies, expanding reimbursement coverage for lvads. Major trends in the forecast period include increasing adoption of continuous flow lvads, rising use of lvads as destination therapy, growing focus on miniaturized implantable pumps, expansion of remote patient monitoring capabilities, enhanced emphasis on device durability and longevity.
The increase in healthcare expenditures is expected to drive the growth of the left ventricular assist device market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare spending can facilitate the advancement and development of various health-related products, including left ventricular assist devices. As healthcare expenditures rise, they will positively impact the growth of the left ventricular assist device market. For example, in June 2025, data from the Centers for Medicare & Medicaid Services (CMS), a United States-based federal agency, indicated that national health spending rose by 7.5% in 2023 to reach $4.9 trillion, representing 17.6% of the United States gross domestic product. Thus, the rise in healthcare expenditures is propelling the growth of the left ventricular assist device market.
Companies active in the left ventricular assist devices space are increasingly concentrating on the development of next-generation technologies, including wave membrane-based systems, as alternatives to conventional rotary LVADs. Wave membrane solutions are designed to mimic natural cardiac pulsatility and blood flow dynamics, closely replicating the function of a healthy heart and potentially reducing complications associated with continuous-flow devices.For instance, in September 2025, CorWave SA, a France-based medical device company, successfully performed the first human implantation of its Left Ventricular Assisting System (LVAS) at St Vincent's Hospital in Sydney. The system delivered complete cardiac support by effectively unloading the left ventricle while maintaining an aortic pulse pressure of 25.5 +- 6.1 mmHg and enabling consistent aortic valve opening. The device met its primary study endpoints without any device-related adverse events at 30 days, and the patient subsequently underwent a successful heart transplant after 84 days of support. This development marks a significant advancement in durable mechanical circulatory support through the delivery of safe, physiological pulsatile blood flow.
In March 2025, Abbott Laboratories, a United States-based healthcare technology company, entered into a collaboration agreement with Cadrenal Therapeutics, Inc. for an undisclosed value. Through this partnership, Abbott sought to support Cadrenal in the execution of a pivotal clinical trial evaluating tecarfarin in patients implanted with HeartMate 3(TM) LVADs, thereby strengthening its role in advanced heart failure care and clinical research. Cadrenal Therapeutics, Inc. is a United States-based biopharmaceutical company focused on the development of novel anticoagulant therapies, including tecarfarin, specifically for patients using cardiovascular devices such as left ventricular assist devices.
Major companies operating in the left ventricular assist devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, St. Jude Medical, MAQUET GmbH & Co., LivaNova Plc, Thoratec Corporation, Abiomed Inc, Berlin Heart GmbH, BioVentrix, Cleveland Heart Inc., Jarvik Heart Inc., CorWave SA, SynCardia Systems LLC, NuPulseCV Inc., Fineheart, Procyrion Inc, Carmat SA, BiVACOR Inc, Cardiac Assist Inc., Leviticus Cardio Ltd., Calon Cardio-Technology Ltd, Evaheart Inc., Sunshine Heart Inc., CH Biomedical Inc.
North America was the largest region in the left ventricular assist devices market in 2025. The regions covered in the left ventricular assist devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the left ventricular assist devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The left ventricular assist devices market consists of sales of rechargeable left ventricular assist devices, non-rechargeable left ventricular assist devices, heart pumps, and controllers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Left Ventricular Assist Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses left ventricular assist devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for left ventricular assist devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The left ventricular assist devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.